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Abstract  
Objectives: Optimal treatment success rates are critical to end tuberculosis in Namibia. 
Despite the scale-up of high quality DOTS in Namibia, treatment success falls short of the 
global target of 90%. Consequently, the objective of this study was to ascertain the 
predictors of treatment success rates under DOTS in Namibia to provide future direction. 
Methods: A nation-wide comparative analysis of predictors of treatment success was 
undertaken. Tuberculosis cases in the electronic tuberculosis register were retrospectively 
reviewed over a 10-year period, 2004-2016. The patient, programmatic, clinical and 
treatment predictors of treatment success were determined by multivariate logistic 
regression modeling using R software.  
Results: 104,603 TB cases were registered at 300 DOTS sites in 37 districts. The 10-year 
period treatment success rate was 80%, and varied by region (77.2%-89.2%). The patient’s 
sex and age were not significant predictors of treatment success. The independent 
predictors for treatment success as were: Region of DOTS implementation (p=0.001), type 
of DOT supporter (p<0.001), sputum conversion at 2 months (p=0.013), DOT regimen 
(p<0.001), cotrimoxazole prophylaxis (p=0.002) and HIV co-infection (p=0.001).  
Conclusion: Targeted programmatic, clinical and treatment interventions are required to 
enhance DOTS treatment success in Namibia. These are now ongoing. 
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1. Introduction 
 
Tuberculosis (TB) is the leading cause of death worldwide from an infectious disease1–3. In 
2015 alone, the WHO estimated that TB killed approximately 1.8 million people globally; 
95% of these deaths occurred in developing countries such as Namibia4.  However, TB can 
be cured5–8, and the World Health Organisation (WHO) and the United Nations Sustainable 
Development Goals (SDGs) for 2030 calls for a 90% reduction in deaths and an 80% 
reduction in incidence rates by 2030 versus 20159,10.  The SDGs use treatment success 
rates (TSR), i.e. proportion of patients that are cure or complete treatment, and the case 
detection rate (CDR), i.e. the percentage of TB cases notified against the estimated number 
cases for that year, as yardsticks for the control of TB.  
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Global initiatives have expanded DOTS (i.e. Directly Observed Therapy Short-course 
strategy) services and markedly improved CDR and TSR in lower and middle income 
countries (LMICs) including Namibia11–15. Nevertheless, although TB incidence rates have 
been decreasing across countries, Namibia remains a high TB burdened country4. In 
addition, despite the 100% scale-up of high quality and community-based Directly Observed 
Treatment (DOT), Namibia still falls short of the national and global targets for TSR of 
95%13,16. Recent analysis suggests that TSR in Namibia have reached a maximum of less 
than 95% global bench mark, and improvements have been marginal in the past 
decade11,15,17. TSR are even lower among the retreatment and smear negative cases13,18. 
Consequently, these sub-optimal treatment success rates are a major concern towards 
eliminating TB in Namibia. Moreover, stagnation in TSR in Namibia in the past decade 
(2004-2015) coincides with the rising burden of drug resistant tuberculosis (DR-TB)19. 
Evidence in Namibia and other LMICs suggests that current DOTS strategies are not 
comprehensive enough to “End TB” by 2035 2,11,20–24.  
 
However, there are conflicting reports on the impact of the various risk-factors in different 
populations including pharmacokinetic variability , socio-demographics and baseline clinical 
characteristics25–27.To date, the magnitude and impact of these risk factors on treatment 
outcomes has not been systematically evaluated in Namibian and other LMICs where the 
burden of TB remains high9. In view of this, the objective of this study was to ascertain the 
predictors of treatment success rates under DOTS in Namibia to provide future direction 
 
2. Methods 
2.1 Study design and population 
 
A retrospective comparative analysis was carried out to determine the predictors of DOT 
treatment success and cure/treatment completion rates among cohorts of TB cases initiated 
on first-line regimens. The study subjects were all new and retreatment cases registered in 
the national electronic TB register (ETR) of Namibia between the third quarter of 2004/Q3 
and first quarter of 2016/Q1.  
 
In Namibia, high quality DOTS services that include DOT are accessible at all public health 
facilities, i.e. facility based DOT (FB-DOTS) or in all communities, i.e. community based DOT 
(CB-DOTS) in all the14 geographical regions of Namibia. The FB-DOTS services can be 
accessed across all levels of care. These include primary health care (health centers and 
clinics) as well as at district, regional and referral hospitals. On the other hand, CB-DOTS 
services are provided by CB-DOTS workers that include DOT supervisors, DOT Nurses and 
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DOT supporters who directly observe TB treatment. They also include health facility nurses, 
work-place peers, and community based workers as well as guardians 
(family/neighbor/relative) and any others preferred by the patient.  
 
DOT regimens are initiated at a health facility and supported either by community and/or 
facility based providers. Data on patient and clinical covariates and treatment outcomes for 
each patient is recorded on TB treatment cards. The data on treatment outcomes is 
subsequently aggregated into health facility, district and regional TB registers/ETR and 
reported every quarter. The National Tuberculosis and Leprosy Programme (NTLP) 
compiles the annual TB treatment outcomes from the regional quarterly reports.    
 
2.2 Tuberculosis DOTS program in Namibia 
In Namibia, TB is managed using the WHO DOTS at health facilities (FB-DOTS) and at the 
community level (CB-DOTS) implemented by NTLP. Namibia achieved a country-wide 
DOTS coverage at all public health facilities, that is 42 hospitals, 34 health centers and 244 
clinics, by 1996. Nonetheless, in 2004 the country reported the highest case notification rate, 
lowest TSR for tuberculosis as well as the emergence of drug resistant TB (DR-TB). 
Consequently in 2004, a CB-DOTS strategy was designed to improve TSR from 65% to 85% 
by 2009 and to 90% by 2015, among other TB indicators under the first and second medium 
term plans (MTP-I, 2004-2009; MTP-II, 2010-2015) for Tuberculosis and Leprosy. CB-DOTS 
was implemented in all districts in partnership with NTLP and community-based HIV/TB 
organizations (CBOs), paving the way for standardized regimens, which were Fixed-Dose 
Combination (FDC) drugs for first-line tuberculosis treatment, the revision of national 
guidelines for case management of tuberculosis and the ETR to report treatment outcomes.  
The diagnosis of TB was by microscopy (i.e. positive sputum smear or culture) and/or clinical 
signs. The FDC regimens for drug susceptible TB (DST) for new adult, new pediatric and 
retreatment cases were 2RHZE/4RHE, 2RHZ/4RH and 1RHZE/2RHZE/5RHE respectively. 
A team of community-based persons comprising of CHW (community healthcare workers), 
i.e. CB-DOT supervisors and FB-DOT supervisors and DOT nurses, DOT field promoters, 
and CB-DOT supporters implemented the CB-DOTS programme at each health district unit. 
The DOT-supporters such as family/relatives or workplace peers or CHWs directly observe 
the administration of the TB-medication at community DOT points, households and 
workplaces. In addition, the quality of CB-DOTS was enhanced through (i) the scale up 
quality assured bacteriology laboratories, up from 30 (1 lab per 67,000 people) in 2004 to 36 
in 2015 to increase case detection, (ii) the production of a CB-DOTS training manual and the 
WHO guideline for TB treatment supporters to standardize treatment with supervision and 
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patient support, (iii) a system for effective supply and management of TB drugs as well as 
(iv) a monitoring and evaluation system for effective measurement.   
 
2.3 Data and statistical analysis 
The main outcome of the study is the treatment success, which refers to the proportion of TB 
cases registered under DOTS between 2004-2015 that successfully completed treatment, 
whether with bacteriological evidence of success (cured, i.e. smear negative at 5 months) or 
without (treatment completed)28,29. Treatment success for extra pulmonary tuberculosis 
(EPTB) in Namibia is mainly determined by treatment completion and/or negative 
microscopy and biopsy results. An unsuccessful outcome in this study referred to TB cases 
recorded as loss-to-follow-up (LTFU), transferred out, failed treatment or died. Cases of DR-
TB are hospitalized and managed according to the treatment guidelines for DR-TB, which 
comprise at least five second line anti-tuberculosis medicines. These include 
levofloxacin, PASA, ethionamide, kanamycin, pyrazinamide, clofazimine, and 
capreomycin for 12-18 months of treatment. 
 
Patient level data on treatment outcomes and covariates including: patient demographics, 
clinical (i.e. disease and laboratory), programmatic (i.e. Facility type, DOTS support, MTP 
strategy), treatment regimen and treatment outcomes were abstracted from the national ETR 
by the principal research team.  
 
Data were retrospectively abstracted over 10-year review period (2004/Q3 and 2016/Q1), 
which coincides with the scale-up to high quality CB-DOTS services in 2005 under the first 
and second medium term plans for TB and leprosy in Namibia. The bacteriological 
assessment of sputum smears was undertaken at three time points, i.e. baseline, at 
completion of the intensive TB treatment (i.e. at 2 or 3 months) and at the completion of TB 
treatment (i.e. at 6 – 8 months). The bacteriological assessment of smears was undertaken 
by the National Institute of Pathology (NIP), a WHO accredited laboratory that services all 
DOTS sites in Namibia. The bacteriological results from the NIP are subsequently validated 
by the facility, district and regional TB care teams. Data on treatment outcomes and 
covariates were exported to RStudio software for statistical analysis. Cases of drug resistant 
tuberculosis and/or missing data on the treatment outcome and/or the covariates of interest, 
i.e. demographic, clinical and treatment and programmatic records, were excluded from 
analysis. 
 
The association between patient, programmatic, clinical and treatment covariates with 
treatment success was determined using bivariate analysis using crude odd ratios (cOR) or 
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Chi-squared test (2). The independent predictors for treatment success were subsequently 
determined using adjusted odds ratios (aOR) using multivariate logistic regression to control 
for confounders for treatment outcomes. The predictors of treatment success are presented 
as odds ratio (aOR) with a 95% Confidence Interval and at a level of significance α=0.05. 
 
2.4 Ethics 
The study was approved by the Research and Ethics Committee of the University of Namibia 
and the Ministry of Health and Social Services (MoHSS). The approvals provided for waiver 
for a written informed consent from the individual TB cases whose records were included 
from the eTR data base.  In order to maintain confidentiality, data were cleaned and coded 
to remove any patient specific identifiers such as names and hospital numbers prior to 
analysis. 
 
3. Results 
 
During the study period (2004/ Q3–2016/Q1), out of the 104,604 TB cases registered, 1 was 
excluded due to missing data on outcome and covariates (Figure 1). 27747 patients had an 
outcome recorded as unavailable and were excluded from the bivariate and multivariate 
analysis and 2974 cases eventually met the criteria for multivariate analysis for all covariates 
and were entered in the model (Figure 1).  
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Figure 1 – Flow chart for inclusion criteria of TB cases 
 
 
Overall, a total 104,603 TB cases were registered at 300 DOTS sites in 37 districts in all 14 
regions of Namibia. This gives an average of 2,226 (range: 1500 – 3500) cases registered 
every quarter. The majority of the cases were registered at primary health care facilities 
(78.9%), predominantly at health centers (62.8%) (Table 1).  
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Table 1: Univariate analysis of covariates with treatment outcome (n=76,856) 
Characteristic Total (%) 
 
Treatment outcome (%) 2 
  
Cramer’s 
V 
p-
value 
Successful Unsuccessful 
Regions 
Khomas 
Erongo 
Ohangwena 
Oshikoto 
Kavango West 
Karas 
Otjozondjupa 
Omaheke 
Zambezi 
Hardap 
Kunene 
Kavango East 
Oshana 
Omusati 
N=76856 
15378(20.0) 
9480 (12.3) 
7520 (9.8) 
7355 (9.6) 
5595 (7.3) 
4888 (6.4) 
4638 (6.0) 
3219 (4.2) 
3057 (4.0) 
3069 (4.0) 
2456 (3.2) 
1538 (2.0) 
1858 (2.4) 
6805 (8.9) 
61338(79.8) 
12105(78.7) 
7588 (80.0) 
5903 (78.5) 
5885 (80.0) 
4335 (77.5) 
3859 (78.9) 
3698 (79.7) 
2822 (87.7) 
2726 (89.2) 
2522 (82.2) 
1897 (77.2) 
1135 (78.7) 
1508 (81.2%) 
5355 (78.7%) 
15518(20.2) 
3273(21.3) 
1892 (20.0) 
1617 (21.5) 
1470 (20.0) 
1260 (22.5) 
1029 (21.1) 
9402 (0.30) 
397 (12.3) 
331 (10.8) 
547 (17.8) 
559 (22.8) 
403 (26.2) 
350 18.8% 
145021.3% 
 
393.3 
 
0.07 
 
0.000* 
MTP period 
MTP-I 
MTP-II 
 
36657 
40199 
 
28766(78.5) 
32572(81.0) 
 
7891(21.5) 
7627(19.0) 
 
77.6 
 
0.03 
 
0.000* 
DOT facility level 
Hospital 
Health Center 
Clinic 
 
16189 (16.1) 
12378 (16.1) 
48289 (62.8) 
 
12348(76.3) 
9750(78.8) 
39240(81.3) 
 
3841(23.7) 
2628(21.2) 
9049(18.7) 
 
197.0 
 
0.05 
 
0.000* 
TB registration status  
Previously registered  
Patient not registered 
 
169 (0.23) 
76687 (98.8) 
 
33(19.5) 
61305(79.9) 
 
136(80.5) 
15382(20.1) 
 
382 
 
0.07 
 
0.000* 
Gender  
Female 
Male 
 
32556(42.1) 
44300(57.9) 
 
26352(80.9) 
34986(79.0) 
 
6204(19.1) 
9314(21.0) 
 
45.1 
 
0.02 
 
0.000* 
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Patient’s age 
0 - 04 years 
05 – 14 years 
15 – 24 years 
25 - 34 years  
35 - 44 years 
45 – 54 years 
55 – 64 years 
65+ years 
 
4878(6.3) 
4167(5.4) 
9260(12.1) 
21942(28.6) 
18558(24) 
9462(12.3) 
4498(5.9) 
4091(5.4) 
 
4191(85.9) 
3729(89.5) 
7766(83.9) 
17564(80.0) 
14467(78.5) 
7292(77.1) 
3355(74.6) 
2874(70.3) 
 
687(14.1) 
438(10.5) 
1494(16.1) 
4378(20.0) 
3991(21.5) 
2170(22.9) 
1143(25.4) 
1217(29.7) 
 
822.6 
 
0.10 
 
0.000* 
Patient aged < 5 years 
Yes 
No 
 
70415(91.6) 
6441(8.4) 
 
5596(86.9) 
55742(79.2) 
 
845(13.1) 
14673(20.8) 
 
218.2 
 
0.05 
 
0.000* 
Treatment category 
New patient 
Retreatment 
 
62469(87.6) 
9567(12.4) 
 
51161(81.9) 
6695(70) 
 
11308(18.1) 
2872(30.0) 
 
745.4 
 
0.10 
 
0.000* 
TB case registered 
New patient 
Failure 
Previously treated 
Readmission 
Recurrent TB 
Relapse TB 
 
62469(81.3) 
675(0.9) 
3508(4.6) 
1043(1.4) 
1313(1.7) 
7848(10.2) 
 
51161(81.9) 
370(54.8) 
2509(71.5) 
674(64.6) 
974(74.2) 
5650(72.0) 
 
11308(18.1) 
305(45.2) 
999(28.5) 
369(35.4) 
339(25.8) 
2198(28) 
 
1053 
 
0.11 
 
0.000* 
Baseline sputum smear 
Smear negative (-) 
Smear positive (+) 
Smear not done  
 
14453(18.8) 
36358(47.3) 
26042(33.9) 
 
11544(79.9) 
29165(80.2) 
20629(79.2) 
 
2909(20.1) 
7193(19.8) 
5416(20.8) 
 
9.7 
 
0.01 
 
0.008* 
Class of smear done 
EPTB No smear 
PTB No smear 
PTB Smear negative (–) 
PTB Smear negative (+) 
 
14733(19.2) 
13457(17.5) 
12325(16.0) 
36341(47.3) 
 
11993(81.4) 
10423(77.5) 
9772(79.3) 
29150(80.2) 
 
2740(18.6) 
3034(22.5) 
2553(20.7) 
7191(19.8) 
 
75.3 
 
0.03 
 
0.000* 
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Microscopy (Pre-
treatment) 
Negative - 
Positive + 
Missing result 
 
 
15971(20.8) 
34839(45.3) 
26046(33.9) 
 
 
12832(80.3) 
27876(80.0) 
20630(79.2) 
 
 
3139(19.7) 
6963(20.0) 
5416(20.8) 
 
 
9.6 
 
 
0.01 
 
 
0.008* 
TB Classification 
EPTB 
PTB 
 
14733(19.2) 
62123(80.8) 
 
11993(81.4) 
49345(79.4) 
 
2740(18.6) 
12778(20.6) 
 
28.7 
 
0.02 
 
0.000* 
TB regimen initiated  
2HRZE/4HR (A) 
2HRZE/1HRZE/5HRE (A) 
2HRZE/1HRZE/5HR (C) 
2HRZ/4HR (C) 
Other regimen 
 
57238(74.5) 
14006(18.2) 
342(0.45) 
4914(6.4) 
356(0.5) 
 
46673(81.5) 
9883(70.6) 
288(84.2) 
4251(86.5) 
243(68.3) 
 
10565(18.5) 
4123(29.4) 
54(15.8) 
663(13.5) 
113(31.7) 
 
1020 
 
0.12 
 
0.000* 
DOT supporter/type 
Guardian (relat/neigh) 
Workplace 
Health Facility 
Community H/Worker 
Other 
 
28546(48.9) 
682(1.2) 
27410(46.9) 
1409(2.4) 
358(0.6) 
 
23480(82.3) 
566(83.0) 
21462(78.2) 
1230(87.3) 
257(71.8) 
 
5066(17.7) 
116(17.0) 
5948(21.7) 
179(12.7) 
101(28.2) 
 
201.6 
 
0.06 
 
0.000* 
HIV status 
Negative 
Positive 
Unknown 
 
25476(44.0) 
27704(47.9) 
4676(8.1) 
 
21752(85.4) 
21243(76.7) 
3713(79.4) 
 
3724(14.6) 
6461(23.3) 
963(20.6) 
 
652.1 
 
0.11 
 
0.000* 
Patient on HAART 
Yes 
No 
 
16741(62.9) 
9894(37.1) 
 
13184(78.8) 
7713(78.0) 
 
3557(21.2) 
2181(22) 
 
2.3 
 
0.01 
 
0.127 
HIV IPT exposure 
Yes 
No 
 
338(3.2) 
10382(96.9) 
 
264(78.1) 
8256(79.5) 
 
74(21.9) 
2126(20.5) 
 
0.4 
 
0.01 
 
0.526 
HIV CPT exposure       
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No 
Yes 
5065(17.6) 
23773(82.4) 
4103(81.0) 
18382(77.3) 
962(19.0) 
5391(22.7) 
 
33 
 
0.034 
 
0.000* 
Developed MDR – TB 
Yes 
No 
 
565(0.6) 
76291(99.4) 
 
- 
61338(80.4) 
 
565(100) 
14953(19.6) 
 
2249.
8 
 
0.17 
 
0.000* 
Sputum conversion- at 
2months 
To smear negative - 
Defaulted 
Died during treat 
Remained positive + 
Results not available 
Patient transferred  
 
 
17835(49.2) 
478(1.3) 
1374(3.8) 
2702(7.5) 
13306(36.7) 
556(1.5) 
 
 
16735(93.8) 
- 
- 
1971(72.9) 
10460(78.6) 
- 
 
 
1100(6.2) 
478(100) 
1374(100) 
731(27.1) 
2846(21.4) 
556(100) 
 
 
1206
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0.58 
 
 
0.000* 
Sputum conversion at 
3months 
To smear negative - 
Defaulted 
Died during treat 
Remained positive + 
Results not available 
Patient transferred 
 
 
25262(69.7) 
712(2.0) 
1543(4.3) 
2361(6.5) 
5745(15.9) 
628(1.7) 
 
 
23663(93.7) 
- 
- 
1441(61%) 
4062(70.7) 
- 
 
 
155(6.3) 
712(100) 
1543(100) 
920(39) 
1683(29.3) 
628(100) 
 
 
1558
7 
 
 
0.66 
 
 
0.000* 
       
* = significant p value by Pearson Chi-Square, * = significant p value by Pearson Chi-Square, MTP = medium 
term plans, TB= Tuberculosis, EPTB = extra pulmonary tuberculosis, PTB = pulmonary tuberculosis, IPT= 
Isoniazid Prophylaxis Therapy, CPT=cotrimoxazole prophylaxis, MDR-TB = drug resistant tuberculosis 
 
The number of cases registered by district ranged between 262 and 20,368, with districts in 
urban, coastal or border settings, such as Khomas, Erongo and Ohangwena regions, 
registering higher numbers of TB patients (32.3%). The number of TB cases registered per 
quarter was significantly higher during the implementation of the first medium term plan for 
tuberculosis (i.e. MTP-I, 2004-2009) than the second (MTP-II, 2005-2010) (Table 1, 
Supplement A). Most of the cases were male (57.9%), aged between 25-44 years (52.6%) 
and about half were co-infected with HIV (47.9%), which is seen as high, with HIV positive 
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patients appreciably more likely to have treatment failure (p<0.000). This was also seen in 
the multivariate analysis (Table 2). However, no difference if HIV patients are on HAART 
(p=0.127) (Table 1).  
 
Most TB cases were categorized as new (87.6%), i.e. had never received treatment for TB, 
or had taken treatment for not more than one month, and had pulmonary TB (PTB, 80.8%) 
compared to EPTB. One third of the cases did not have sputum smear evaluated (33.9%) at 
the start of TB treatment. Most patients were initiated on 2RHZE/4RH (74.5%) compared to 
2RHZE/4RHE. Guardians (i.e. family members or relatives) of the TB cases (48.9%) were 
the main DOT supporters, compared to DOT nurses or workplace peers.  
 
Of the 104,603 TB cases, 73.5% had treatment outcomes registered in the electronic 
treatment record. The treatment success rate for the review period was 80% (range: 77.2% - 
89.2% by region), which was registered as treatment completion (61.3%) rather than cure 
(38.7%) (Figure 2).  Death and LTFU were the most prevalent unsuccessful treatment 
outcomes (Table1). The mean TSR was significantly higher among TB cases registered at 
primary health care (PHC) facilities (i.e. Health centers, 72.4% and clinics, 74.5%) compared 
to hospital, 71.4 (p<0.001). Though the TSR were above 80% in most regions (8/14), no 
region achieved the 90% global target for TSR. Only two regions out of 14, Zambezi and 
Omaheke, surpassed the 85% WHO TSR targets (Figure 3).  
 
Figure 2: Categories of treatment outcomes (n=76856, not evaluated = 27747) 
 
Failed
3%(2,199)
Tansfered out
4%(3,088)
Defaulted
5%(3,775)
Died
8% (6,456)
Cured
31% (23,737)
Completed
49% (37,599)
Treatment
success
80%(61336)
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Figure 3: Period prevalence of TB Treatment outcomes by regions in Namibia 
 
 
 
Treatment success was statistically significantly (p<0.001) associated with all programmatic, 
clinical, patient demographic and treatment covariates (Table 1), except for prior exposure to 
isoniazid prophylactic therapy (IPT, p=0.526) or co-medication with antiretroviral therapy 
(ART, p<0.127) (Table 1). 
 
A test of the full logistic regression model (Table 2), against a constant only model, was 
statistically significant, indicating that the programmatic, clinical, patient and treatment 
predictors as a set reliably distinguished between successful and unsuccessful treatment 
outcomes (2 = 1401.3, p<0.001 with df = 48). A good relationship between prediction and 
grouping by successful (1) and unsuccessful outcome (0) was indicated by a Nagelkerke’s 
R2 score of 0.597 as well as a non-significant Hosmer and Lemeshow Test (2 = 11.9, 
p=0.156 with df = 8).  
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Table 2: Multivariate analysis of predictors of tuberculosis treatment outcomes 
Covariate Wald df OR (95%,CI) p-value 
Medium Term Plan 
MTP-I 
MTP-II 
 
0.3 
 
1 
 
1.1(0.8,1.5) 
1 
 
0.608 
Region 
Khomas 
Kavango West 
Zambezi 
Otjozondjupa 
Erongo 
Karas 
Hardap 
Kunene 
Ohangwena 
Omaheke 
Oshikoto 
Oshana 
Omusati 
Kavango East 
36.0 
2.1 
1.0 
2.0 
6.3 
1.0 
0.5 
0.7 
2.5 
2.4 
0.8 
0.0 
0.4 
1.4 
13 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
2.8(0.7, 11.3) 
0.8(0.4,1.3) 
1.5(0.9,2.6) 
2.8(1.3,6.4) 
0.7(0.3,1.7) 
0.7(0.3,1.7) 
0.4(0.0,3.5) 
0.6(0.3,1.1) 
2.0(0.8,4.9) 
0.7(0.3,1.6) 
125109200 
1.8(0.3,12.5) 
1.4(0.8,2.6) 
1 
0.001* 
0.147 
0.324 
0.158 
0.012* 
0.328 
0.465 
0.396 
0.112 
0.121 
0.385 
1.000 
0.540 
0.237 
Facility level 
Hospital 
PHC Clinic 
Health Center 
1.7 
1.1 
1.6 
2 
1 
1 
 
1.4(0.8, 2.4) 
1.3(0.9, 2.0) 
1 
0.428 
0.287 
0.211 
Patients sex 
Male 
Female 
 
1.7 
 
1 
 
0.8(0.6,1.1) 
1 
 
0.197 
Patient age category 
0 to 04 
05 to 14 
15 to 24 
25 to 34 
35 to 44 
9.7 
2.0 
1.4 
2.0 
3.1 
0.6 
7 
1 
1 
1 
1 
1 
 
7.6(0.5,121.6) 
2.4(0.6,10.5) 
1.6(0.8,3.2) 
1.7(0.9,3.2) 
1.3(0.7,2.4) 
0.206 
0.153 
0.243 
0.155 
0.080 
0.450 
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45 to 54 
55 to 64 
65+ 
0.3 
3.3 
1 
1 
1.2(0.6,2.3) 
2.1(0.9,4.4) 
0.602 
0.070 
Previously registered 
No 
Yes 
 
0.1 
 
1 
 
0.6(0.0,9.0) 
1 
 
0.726 
Diagnostic classification 
Failure 
Readmission 
Relapse 
1.7 
0.5 
1.3 
2 
1 
1 
 
0.7(0.3,1.8) 
0.6(0.3,1.4) 
1 
0.429 
0.467 
0.246 
Pulmonary 
Lymph Nodes 
Miliary 
Other Sites 
Pleura 
Bones/Joints 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
5 
1 
1 
1 
1 
1 
0.0(0.0,1.0) 
1.3 
0.4 
0.4 
0.0 
1.000 
0.999 
1.000 
1.000 
1.000 
0.999 
DOT Provider 
Guardian (relative, neighbor) 
Workplace 
Health Facility 
Community health worker 
Other 
27.4 
25.3 
12.8 
20.4 
10.5 
4 
1 
1 
1 
1 
 
10.8(4.3,27.2) 
25.6(4.3,151.8) 
8.6(3.4,22.0) 
10.6(2.5,44.4) 
1 
0.000* 
0.000* 
0.000* 
0.000* 
0.001* 
TB regimen initiated 
2 HRZE/4 HR 
2 HRZES/1 HRZE/5 HRE (Adults) 
2 HRZ / 4 HR 
41.7 
0.9 
0.0 
0.0 
3 
1 
1 
1 
 
3.2(0.3,34.5) 
1.0(0.1,11.1) 
1 
0.000* 
0.333 
0.999 
Smear non conversion  
Yes 
No 
459.1 1 0.02(0.01,0.03) 
1 
0.000* 
Sputum conversion 2 months 
Converted to smear negative 
Remaining smear positive 
Defaulted+Died+Transfered+Not available 
8.7 
2.8 
7.9 
2 
1 
1 
0.7(0.5,1.1) 
0.5(0.3,0.8) 
1 
0.013* 
0.092 
0.005 
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Antiretroviral Treatment 
No  
Yes 
0.8 1 0.8(0.6,1.2) 
1 
0.363 
Cotrimoxazole Prophylaxis 
No 
Yes 
9.6 1 0.4(0.2,0.7) 
1 
0.002* 
IPT (isoniazid) exposure 
No 
Yes 
 
0.5 
 
1 
 
1.2(0.7,2.6) 
1 
 
0.464 
HIV status 
Negative 
Positive 
Unknown 
26.1 
0.1 
12.1 
2 
1 
1 
 
1.1(0.5,2.2) 
0.2(0.1,0.5) 
1 
0.000* 
0.813 
0.001* 
Constant 0.000 1 0.121 1.000 
 
a. Variable(s) entered on step 1: Medium Term Plan strategic plan, I or II, REGION, FACLEVEL, PREVREGT, SEX, 
REGIMENTYPE, DIAGCLASS, SITEINFECTEDTB, MDRPatientt, DOTTYPE, PtAgegroup, NOTCONVERTED, 
SPUTUM2mon, ARTtreat, CPTtherapy, IPTrecieved, HIVSTATUS. 
 
The prediction success of the model overall was 90.48% with 95.1% for successful treatment 
outcome and 71.2% for non-successful treatment outcome. The Wald criterion demonstrated 
consistency between TB treatment success and, the regions of implementation of DOTS in 
Namibia (p<0.001) – with some regions such as Otjiwarongo (OR=2.8, 95%CI:1.3,6.4) 
having significantly higher TSR than others, the first-line TB regimen initiated (p<0.001), the 
type of DOT provider (p<0.001) with TSR being highest for DOT implemented at the 
workplace (OR=25.6, 95%CI: 4.3, 151.8), non-conversion of sputum at 2 months (OR=0.2, 
95%CI: 0.01, 0.03), co-infection with HIV (OR=0.2, 95%CI: 0.01, 0.5) and exposure to 
cotrimoxazole prophylaxis therapy (CPT - OR=0.4, 95%CI: 0.2, 0.7).   
 
The patients’ demographics, health facility level and prior TB registration and/or exposure to 
TB medication or IPT and diagnostic classifications were not significant predictors for 
treatment outcomes of tuberculosis. The covariates of the region of the DOTS service, HIV 
coinfection, TB regimen, cotrimoxazole prophylaxis and sputum conversion at 2 months 
were identified as independent risk factors for successful treatment outcomes for first line 
regimens (Table 2). 
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4. Discussion 
 
The study determined patient, programmatic and diagnostic predictors of treatment success 
of first-line TB treatment in Namibia (Table 1). The period prevalence of DOTS treatment 
success in Namibia was 80%, which varied across the regions in Namibia. However, this 
falls short of the global TSR targets to End TB in Namibia. 
  
These findings are consistent with the WHO global tuberculosis reports on in LMIC and 
Namibia that depict marginal improvements in past five years17,29.  However, of concern, is 
that majority of the treatment success end points (61%) in Namibia were due to treatment 
completion rather than cure (Figure 2). Previous studies in the Omaheke region in Namibia, 
and in other LMICs such as Uganda and South Africa, suggest that low acceptance and poor 
implementation of CB-DOTS are due to social, cultural, programmatic factors 21,30. These 
factors together with access to DOTS services31 are important drivers of poor TB treatment 
outcomes18,20,32. This finding suggests the need to strengthen bacteriological monitoring of 
patients on treatment across all regions in Namibia to optimize case management, as 
recommended by the global End TB strategy31.  
 
This study showed a significant association between TB treatment success and all 
programmatic, patient demographics such as sex and age, clinical (HIV coinfection, TB 
diagnosis and sputum conversion at month 2/3 and treatment covariates except IPT and 
prior ART exposure (Table 1). Similar studies in South Africa and Uganda25,26 have also 
associated poor treatment outcomes to the male gender, HIV co-infection, diagnostic and 
the sputum conversion at 2 months as well as the WHO TB regimen used33. In addition, 
coinfection with HIV and/or diabetes among TB patients, patient related demographic 
characteristics34,35, and pharmacokinetic variability among populations36. In addition in this 
study, poor treatment outcomes were as a result of defaulting of treatment and death. 
Previous studies have associated high rates of death and defaulting among TB patients to 
be due to the inappropriate choice of  TB regimens37,38, HIV co-infection 39,40, adverse drug 
effects41–43 and the lack of screening and monitoring systems6,18,44,45. 
 
A multivariate logistic regression analysis indicated that the patient’s HIV status, TB regimen, 
the type DOT provider, prior cotrimoxazole prophylaxis, sputum conversion at 2 months and 
the region, were significant predictors of TB treatment outcomes (Table 2). Our findings 
though differ from other studies that found that patient’s demographics including their 
age41,46 and male-gender27,46-49, as well as the TB diagnostic category, and level of health 
facility care, were significant predictors of TSR. However, our findings are similar to others 
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that have reported a positive HIV status and sputum non-conversion at month 2 as important 
risk factors for poor treatment outcomes.  
 
This study also gives conflicting reports on the effect of gender on TB treatment success to 
studies by Nakiyingi et al. and others in Uganda that indicated that male patients are at 
increased risk of poor outcomes 25,26. However, in our study, patients who received treatment 
through a work placed based DOTS care increased their TSR by more than three times 
compared to other types of DOT providers. The results indicate the importance of optimizing 
the TB regimens36,41,50, strengthening the support DOTS support system and instigating a 
system to screen and monitor for risk for poor treatment outcomes among patients with HIV 
co-infection, and prior exposure to cotrimoxazole, to maximize the outcome of DOTS. The 
regional variation in TSR may be due population related characteristics and/or access and 
quality of health care at these facilities.  We will be exploring this further in future studies. 
 
The fact that bacteriological monitoring is not routinely undertaken in 26% of the TB cases 
may also predispose patients to poor outcomes. There is also a need to establish the HIV 
status of the patient as a certain proportion of patients were initiated on treatment with 
unknown status. There is also a need to establish a system for screening for  sub-optimal 
serum levels of first line regimens as well as pharmacovigilance monitoring 41 given 
concerns with adverse drug reactions43. The objective being to make appropriate dosage 
adjustments to improve outcomes. Several studies have shown that up to 75% of the 
patients do not achieve optimal drug levels and adjustments of doses will improve outcomes.   
 
Our findings are also different from a number of other studies that show favourable treatment 
outcomes among patients on ART and IPT and CPT. These differences may be due to the 
fact that our study was of a retrospective design that utilized national wide routine data 
compared to RCTs were the conditions of the study are controlled. The regional variation in 
TSR potentially indicates the heterogeneity of our study population that may have effects on 
the TSR. We also plan to follow this up in future research studies as the rationale will provide 
additional guidance on ways to further improve treatment outcomes in Namibia. 
 
We accept this study has a number of limitations. The principal one includes the 
retrospective design where the accuracy of the data collected cannot be validated and there 
were missing data on several covariates including possible adverse drug reactions and the 
type of ART regimen. We will be undertaking a separate study to investigate the side-effects 
of treatment regimens as well as undertaking a separate analysis of MDR-TB cases. 
However, the study gives a true reflection of current routine clinical practice in Namibia for 
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these patients and describes the limitations of the current DOTS interventions using national 
wide data aggregated over a 10-year period. As a result, we believe that our findings are 
important in providing evidence which can guide efforts to improve treatment outcomes 
among patients at risk of poor outcomes, which Namibia is already starting to review in its 
third strategic plan. 
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Supplement A:  National Strategic Plan on Tuberculosis (MTP-I and MTP-II) 
 
 MTP-I: First Medium Term strategic Plan for 
TB 
MTP-II: Second Medium Term strategic 
Plan for TB 
Strategic result 1 Treatment success (cure + completion) rate 
increased from 65% to 85% for all patient 
categories by 2009 
 NTCP started rolling out CB-DOT in 2005  
 Introduction of Fixed Dose Combinations 
(FDCs) for first line tuberculosis treatment 
High quality TB DOTs and leprosy services 
expanded and enhanced,  
 Review of TB treatment guidelines 
from 2RHZE/4RH to 2RHZE/4RHE 
 TSR of 87% achieved for all patient 
categories on firstline treatment 
 Uninterrupted supply of TB medicines 
Strategic result 2 All tuberculosis suspects and patients have 
access to timely and quality-assured TB 
laboratory services 
2. Increased access to high quality TB/HIV 
treatment and care intervention,  
Strategic result 3 Adequate and competent human resources for 
TB control at all levels 
3. Programmatic management of drug-
resistant TB improved and scaled up,  
 DOT system for DR-TB patients 
Strategic result 4 Management capacity of National Tuberculosis 
control program (NTCP) strengthened and 
adequate at all levels 
4. General health systems strengthened 
and effectively supporting TB and leprosy 
services,  
Strategic result 5 Operational research and epidemiological 
surveillance capacity in place and supporting 
management and M&E 
5. Partnership for TB control and leprosy 
eradicated strengthened, and  
Strategic result 6 80% of the general population have a 
satisfactory level of knowledge on tuberculosis 
disease and services for appropriate health-
seeking behaviour 
6. Communities and people with TB and 
leprosy empowered.  
Strategic result 7 All PLWHA and PLWTB have access to a 
continuum of care and support services for TB 
and HIV/AIDS, in all health care facilities and 
home-based care services in public and private 
sector by 2009 
 
Strategic result 8 Financial resources for TB control in public and 
private sector are adequate 
Strategic result 9 Specific TB control strategies implemented in 
sectors with high tuberculosis burden by 2009 
Adapted from the Medium Term Plan (MTP-I and MTP-II) ;  
MTP-I (2004-2009): Based on the DOTS strategy  and MTP-II (2010-2015): Based on the Stop TB strategy and 
the Enhanced Global strategy 
 
 
 
 
